CODA 001

Drug Profile

CODA 001

Alternative Names: Antisense deoxynucleotide oligomer - CoDa Therapeutics; Antisense oligonucleotide compound - CoDa Therapeutics; CODA001; Nexagon

Latest Information Update: 04 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CoDa Therapeutics (NZ); CoDa Therapeutics Inc
  • Developer CoDa Therapeutics Inc
  • Class Antisense oligonucleotides; Antiulcers
  • Mechanism of Action Gap junction modulators; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Wounds
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic foot ulcer; Leg ulcer; Wounds

Most Recent Events

  • 04 Oct 2015 No recent reports of development identified - Phase-II for Wounds (in patients with persistent corneal epithelial defects) in USA (Topical)
  • 04 Oct 2015 No recent reports of development identified - Phase-I for Wounds (in patients who underwent bilateral photorefractive keratectomy for myopia correction) in New Zealand (Topical)
  • 04 Oct 2015 No recent reports of development identified - Phase-II for Diabetic foot ulcer in Ukraine, Russia and USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top